NRIX
Nurix Therapeutics Inc
23.70$
-1.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 259.1% | 327.9% | 301.5% | 404.6% | 440.7% | 506.1% | 377.5% | 177.3% | 63.3% | 34.1% | 1,345.8% | 42.6% | 265.5% | |
| -159.1% | -227.9% | -201.5% | -304.6% | -340.7% | -406.1% | -277.5% | -77.3% | 36.7% | 65.9% | -1,245.8% | 57.4% | -165.5% | |
| 259.1% | 327.9% | 301.5% | 404.6% | 440.7% | 506.1% | 377.5% | 177.3% | 1,091.0% | 595.9% | 1,345.8% | 969.3% | 921.5% | |
| 57.5% | 71.1% | 71.1% | 96.8% | 93.1% | 80.7% | 63.2% | 32.4% | 166.7% | 100.5% | 233.7% | 172.4% | 155.1% | |
| 57.5% | 71.1% | 71.1% | 96.8% | 93.1% | 80.7% | 63.2% | 32.4% | 1,194.3% | 677.9% | 233.7% | 1,099.2% | 816.9% | |
| -216.7% | -299.1% | -272.6% | -401.4% | -433.8% | -486.7% | -340.7% | -109.7% | -1,157.7% | -612.0% | -1,479.4% | -1,041.7% | -982.4% | |
| – | 52.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -200.3% | -276.8% | -249.8% | -367.6% | -388.3% | -440.7% | -305.4% | -96.9% | -1,094.8% | -576.1% | -1,394.3% | -993.1% | -929.2% | |
| 18.5% | 52.0% | 0.5% | 0.7% | 0.7% | 0.1% | – | 1.7% | – | – | – | -3.0% | – | |
| -200.3% | -276.8% | -250.3% | -368.4% | -388.9% | -440.7% | -305.4% | -98.7% | -1,094.8% | -576.1% | -1,394.3% | -990.1% | -928.4% | |
| -189.7% | -273.3% | -237.5% | -348.4% | -369.2% | -431.3% | -292.6% | -91.8% | -1,031.4% | -507.9% | -1,333.9% | -950.5% | -869.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.